„DON“ compounds

Z-(D)-DON-Val-Pro-Leu-OMe, Z-(D)-DON



Order
Quantity
Price
Status
10 mg 450 € available


Documents
Art. No. Z011
Synonym This compound is 1,000 fold less potent than the parent molecule Z-DON-VPL-OMe
(Z006)
Molecular Formula C31H44N6O8
Molecular Weight 628.72
Purity by HPLC >95 % (214 nm)
Appearance Pale yellow solid
Solubility 100 μM in 2% (v/v) DMSO or 2% (v/v) Ethanol / aqueous buffers.
Pre-dissolve e.g. 3.14 mg (5 μmol) in 1 ml DMSO or 1 ml Ethanol - dilute by adding 49 ml buffer to obtain a 100 μM solution.
Application Biochemical control to Z-DON-VPL-OMe (Z006)
IC50 ~ 20.000 nM (compared to 20 nM for Z-DON-VPL-OMe)
Storage Store at -20°C, desiccate
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy